Research at the RCTC focuses on improving the lives of patients with chronic lung diseases. We have particular expertise in the physiological mechanisms limiting exercise and physical activity and how these contribute to morbidity, mortality and quality of life. In particular, we specialize in phase 2a clinical trials to identify drugs, devices and therapies to benefit physical function in patients with COPD.
Watch veteran newscaster and CBS Senior Contributor, Ted Koppel with his wife, Grace Anne, as they speak about COPD on the CBS Sunday Morning show (November 26, 2017):
Improving the outlook for COPD patients requires a partnership among patients, researchers and healthcare providers. By working together we can speed the discovery of new ways to improve patients' breathing, physical activity and quality of life.
Participation in research may provide new information about your own health, and provides access to cutting-edge therapies.
Below is a list of clinical trials at our Center that are currently open to enrollment.
If you are a patient interested in participation in a clinical trial please contact us to enquire about eligibility or arrange a visit. Consultations may inculde the following:
Sign up for our participant registry, and we will contact you about current or future clinical trials for which you might qualify. Registry enrollment requires a 1 hour visit to our clinic, a medical history and a breathing test. The registry enrolls participants with a history of smoking, with or without a diagnosis of COPD, as well as a limited number of individuals who have never smoked (healthy controls). Please contact us to enroll.
ClinicalTrials.gov identifier NCT03359473
This study aims to determine whether an oral medication that selectively targets skeletal muscle growth can increase leg muscle strength and walking ability in moderate to severe COPD patients.
ClinicalTrials.gov identifier NCT03170232
This is a pilot study will investigate the effect of danirixin tablets on lung function and health related quality of life (HRQoL) in COPD patients with mild to moderate airflow obstruction and a demonstrated history of decline in forced expiratory volume in one second (FEV1). Danirixin is potential anti-inflammatory agent for the treatment of COPD.
ClinicalTrials.gov identifier NCT02845752
This study aims to determine whether a bronchodilator inhaler influences the rate of fatigue development during cycling exercise in moderate to very severe COPD patients.
ClinicalTrials.gov identifier NCT03081156
This study aims to determine whether a bronchodilator inhaler influences pulmonary function, gas exchange and exercise tolerance in moderate to severe COPD patients.
ClinicalTrials.gov identifier NCT02867761
This study aims to determine whether current and former smokers who have shortness of breath but with normal lung function, will derive symptomatic benefit from long-acting bronchodilator therapy, even though they are currently excluded from guidelines on the use of bronchodilator therapy.
This study aims to determine the effects on metabolism and immunity of single actute bout of exercise and of completing a pulmonary rehabilitation program in COPD patients compared with age-matched controls. Exercise capacity, muscle mass, muscle strength and power, resting metabolic rate and fatty acid oxidation will also be measured.
ClinicalTrials.gov identifier NCT00608764
External Link: http://www.copdgene.org/
This nationwide multicenter study aims to identify the genetics behind why some smokers get COPD and other do not. The study is still open to enrollment, but only of participants who have never smoked.
This study aims to determine whether a non-invasive device can be used to measure the effectiveness of breathing during exercise in patients with COPD, pulmonary hypertension and health controls.
ClinicalTrials.gov identifier NCT02587351
External Link: http://blockcopd.org/
βLOCK-COPD is a placebo controlled clinical trial that aims to examine the role of beta-blockers in COPD treatment. The study will enroll approximately 1028 patients at research centers across the United States including the Rehabilitation Clinical Trials Center at LA BioMed.
ClinicalTrials.gov identifier NCT02719184
This observational study will enroll ex-smokers without airflow limitation, COPD patients and patients with Alpha1-Antitrypsin deficiency. Lung imaging and assessment of blood samples will be investigated in an attempt to identify the factors that influence the progression of lung disease in COPD.
Last updated April 2, 2017